The global axial spondyloarthritis drug market is anticipated to grow at a considerable CAGR of 4.1% during the forecast period. The market is primarily driven by favourable conditions for pharmaceutical producers and the attention of various government agencies on enhancing the current healthcare infrastructure. These will lead to a rise in global demand for various drugs for treatment options for axial spondyloarthritis in the near future. Additionally, significant investment in research and development, favourable reimbursement circumstances, and rising incidences and prevalence may all contribute to market growth. For instance, in March 2019, Certolizumab pegol (CIMZIA), a TNF inhibitor, has been approved by the US Food and Drug Administration for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA.) This is the first and only biologic medicine to be approved for nr-axSpA in the US, giving patients effective treatment who suffered from the condition access to a novel class of treatment.
The majority of established key players in the global axial spondyloarthritis drug market are forming strategic agreements to improve their market position and expand their geographic reach. For instance, in January 2022, Amgen Inc. announced its research collaboration with Generate Biomedicines to find and develop protein therapies for five clinical targets in a variety of therapeutic areas and methodologies.
To Request a Sample of our Report on Axial Spondyloarthritis Drug Market: https://www.omrglobal.com/request-sample/axial-spondyloarthritis-drug-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Type
- By Distribution Channel
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– including AstraZeneca Plc., Eli Lilly and Co., Johnson & Johnson Services, Inc., Novartis AG, Panacea Biotec Ltd., and others.
Axial Spondyloarthritis Drug Market Report Segment
By Type
- Certolizumab Pegol
- Etanercept Biosimilar
- Ixekizumab
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
A full Report of Axial Spondyloarthritis Drug Market is Available @ https://www.omrglobal.com/industry-reports/axial-spondyloarthritis-drug-market
Axial Spondyloarthritis Drug Market Report Segment by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- Abbott
- AbbVie Inc.
- Amgen Inc.
- GlaxoSmithKLine Plc.
- Kyowa Kirin Co., Ltd.
- Merck & Co. Inc.
- Pfizer Inc.
- Sandoz International GmbH
- KYOCERA Corp.
- Sun Pharmaceutical Industries Ltd.
- UCB S.A.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/axial-spondyloarthritis-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
